Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569388 | 0.87 | MAPT (0.62) | LMNAMAPTSMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL3323854 | 0.86 | ALDH1A1 (0.53) | LMNAMAPTGAAPKMHTT | |
| SCHEMBL12788532 | 0.84 | SMN1; SMN2 (0.51) | LMNAMAPTGAAHTTSMN1; SMN2 | |
| SCHEMBL4172495 | 0.83 | MAPT (0.58) | LMNAMAPTSMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL2061231 | 0.83 | LMNA (0.55) | LMNAMAPTGAAPKMHTT | |
| SCHEMBL13965741 | 0.83 | HRH3 (0.48) | LMNASMN1; SMN2ALDH1A1KMT2AKCNH2 | |
| SCHEMBL12788533 | 0.82 | KDM4E (0.58) | LMNAMAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL15956633 | 0.82 | MAPT (0.57) | LMNAMAPTSMN1; SMN2ALDH1A1LTA4H | |
| Hydrochloric Acid SCHEMBL5071255 | 0.82 | MAPT (0.57) | LMNAMAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL12788366 | 0.82 | KCNH2 (0.52) | LMNAMAPTGAAPKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2292621-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292621-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256119-A1 | Vasopressin V1a antagonists | Vantia Limited (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | LMNA 3529/4885MAPT 4674/4885GAA 3812/4885 |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | LMNA 2881/4885MAPT 4727/4885GAA 4166/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | LMNA 2881/4885MAPT 4727/4885GAA 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.